AU2022233178A1 - Compositions and methods for treating polycythemia - Google Patents

Compositions and methods for treating polycythemia Download PDF

Info

Publication number
AU2022233178A1
AU2022233178A1 AU2022233178A AU2022233178A AU2022233178A1 AU 2022233178 A1 AU2022233178 A1 AU 2022233178A1 AU 2022233178 A AU2022233178 A AU 2022233178A AU 2022233178 A AU2022233178 A AU 2022233178A AU 2022233178 A1 AU2022233178 A1 AU 2022233178A1
Authority
AU
Australia
Prior art keywords
subject
polycythemia
alkyl
group
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022233178A
Other languages
English (en)
Inventor
Maria Gabriela BECONI
Vu HONG
John QUISEL
Pavan REDDY
William Jacob SAVAGE
Min Wu
Yi XIANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Disc Medicine Inc
Original Assignee
Disc Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disc Medicine Inc filed Critical Disc Medicine Inc
Publication of AU2022233178A1 publication Critical patent/AU2022233178A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022233178A 2021-03-12 2022-03-11 Compositions and methods for treating polycythemia Pending AU2022233178A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163160412P 2021-03-12 2021-03-12
US63/160,412 2021-03-12
US202163185464P 2021-05-07 2021-05-07
US63/185,464 2021-05-07
PCT/US2022/020038 WO2022192730A1 (en) 2021-03-12 2022-03-11 Compositions and methods for treating polycythemia

Publications (1)

Publication Number Publication Date
AU2022233178A1 true AU2022233178A1 (en) 2023-10-26

Family

ID=83228388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022233178A Pending AU2022233178A1 (en) 2021-03-12 2022-03-11 Compositions and methods for treating polycythemia

Country Status (10)

Country Link
US (3) US20260027107A1 (https=)
EP (1) EP4304596A4 (https=)
JP (1) JP2024509265A (https=)
KR (1) KR20230169981A (https=)
AU (1) AU2022233178A1 (https=)
BR (1) BR112023018403A2 (https=)
CA (1) CA3213395A1 (https=)
IL (1) IL305806A (https=)
MX (1) MX2023010449A (https=)
WO (1) WO2022192730A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230169981A (ko) * 2021-03-12 2023-12-18 디스크 메디슨, 인크. 적혈구증가증을 치료하기 위한 조성물 및 방법
CN116942668A (zh) * 2023-03-17 2023-10-27 天津医科大学 Glyt1抑制剂在治疗器官纤维化中的应用
AU2024339974A1 (en) * 2023-09-15 2026-03-26 Disc Medicine, Inc. Glyt-1 inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180036A1 (ar) * 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
KR20230169981A (ko) * 2021-03-12 2023-12-18 디스크 메디슨, 인크. 적혈구증가증을 치료하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
US20240269132A1 (en) 2024-08-15
US20260027107A1 (en) 2026-01-29
US20250248995A1 (en) 2025-08-07
MX2023010449A (es) 2023-11-09
WO2022192730A1 (en) 2022-09-15
KR20230169981A (ko) 2023-12-18
JP2024509265A (ja) 2024-02-29
EP4304596A1 (en) 2024-01-17
CA3213395A1 (en) 2022-09-15
IL305806A (en) 2023-11-01
EP4304596A4 (en) 2025-02-19
BR112023018403A2 (pt) 2023-10-10

Similar Documents

Publication Publication Date Title
US20240269132A1 (en) Compositions and methods for treating polycythemia
US20250262204A1 (en) Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
US20240325382A1 (en) Compositions and methods for treating anemia associated with a ribosomal disorder
CN118319913A (zh) 用于治疗红细胞增多症的组合物和方法
US20250228827A1 (en) Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
HK40105387A (zh) 用於治疗红细胞增多症的组合物和方法
US20250302823A1 (en) Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors
WO2026064696A1 (en) Compositions and methods for treating myelodysplastic syndrome with glycine transport inhibitors
HK40112808A (zh) 用於治疗与核糖体障碍相关的贫血的组合物和方法
HK40105830A (zh) 用於治疗与核糖体障碍相关的贫血的组合物和方法
CN118319914A (zh) 用于治疗与核糖体障碍相关的贫血的组合物和方法
HK40082113A (en) Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors